IPSEN, OOO

The E-Learning module covers non-clear cell renal cancers' classification, incidence, prognosis, molecular alterations, and current management, emphasizing the need for subtype-specific clinical trials and biomarkers. It details treatments like mTOR and tyrosine kinase inhibitors, MET inhibitors, immune checkpoint inhibitors, and their combinations, highlighting the best response rates with these combinations and the logical approach of MET inhibition in MET-driven tumors.

Ipsen presents data on Bylvay's long-term efficacy and safety in PFIC and ALGS at AASLD 2024, showing sustained improvements in pruritus, serum bile acid levels, height, weight, and sleep.

Ipsen presents data on Bylvay's long-term efficacy and safety in PFIC and ALGS at AASLD 2024, showing sustained improvements in pruritus, serum bile acid levels, height, weight, and sleep measures.

Ipsen presents data at AASLD 2024 on Bylvay's long-term efficacy in PFIC and ALGS, showing sustained improvements in pruritus, serum bile acid levels, height, weight, and sleep measures.

Ipsen presents data on Bylvay's long-term efficacy and safety in PFIC and ALGS at AASLD 2024, showing sustained improvements in pruritus, serum bile acid levels, height, weight, and sleep measures.

Bylvay® (odevixibat) demonstrates sustained improvement in severe itch and serum bile acid levels in PFIC and ALGS patients, with data from PEDFIC 2 and ASSERT-EXT studies presented at AASLD 2024.

Ipsen presents Iqirvo data at AASLD 2024, showing sustained efficacy and safety in PBC patients over 3 years, with improvements in pruritus, fatigue, and sleep. Iqirvo is approved in the U.S., E.U., and U.K. for PBC treatment.

GENFIT presents pre-clinical data on ACLF treatments at The Liver Meeting 2024, including VS-01, SRT-015, CLM-022, and NTZ, and leads key ACLF events. The company anticipates data from four clinical trials by end of 2025, focusing on VS-01, NTZ, and SRT-015. GENFIT also presents NIS2+® data for MASH monitoring.